EG 011

Drug Profile

EG 011

Alternative Names: Ad-VEGF-D; EG011; VEGF-D short-form

Latest Information Update: 23 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ark Therapeutics
  • Class Gene therapies; Ischaemic heart disorder therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor D stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Angina pectoris

Most Recent Events

  • 08 Nov 2012 Discontinued - Phase-I/II for Angina pectoris in Finland (Intracoronary)
  • 16 May 2012 Ark Therapeutics completes the phase I portion of its phase I/IIa trial in Angina pectoris in Finland
  • 25 Aug 2011 EG 011 is available for partnering as of 25 Aug 2011. www.arktherapeutics.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top